MediciNova Highlights Strategic Focus On Non-Dilutive Funding With NIH-Funded ALS Trial And Canadian Long COVID Study, Reports Strong $42.3M Cash Position, And Reaffirms Commitment To Sustainable Growth And Shareholder Transparency
MediciNova Highlights Strategic Focus On Non-Dilutive Funding With NIH-Funded ALS Trial And Canadian Long COVID Study, Reports Strong $42.3M Cash Position, And Reaffirms Commitment To Sustainable Growth And Shareholder Transparency
美第奇新星生物技术强调了其在非稀释融资方面的战略重点，包括由NIH资助的ALS试验和加拿大的长期新冠研究，报告强劲的4230万美元现金状况，并重申对可持续增长和股东透明度的承诺
To our esteemed stockholders,
致我们尊敬的股东，
Since its founding, MediciNova has been clear in its mission to deliver new treatment options to the patients suffering with unmet medical needs. In service of that mission, we have been steadfast in our commitment to both further our science in partnership with some of the greatest minds across the United States, and to do so in a way that preserves capital and provides optimal value to shareholders.
美第奇新星生物技术自创立以来，始终秉承其使命，致力于为患有未满足医疗需求的患者提供新的治疗选择。为实现这一使命，我们始终坚定地与美国一些顶尖智慧合作，推动科学，以一种既保全资本又为股东提供最佳价值的方式。
Our recently announced collaboration to supply our compound MN166 (ibudilast) as part of an NIH-funded expanded access clinical trial is illustrative of this commitment, as it provides the...
我们最近宣布的合作项目，为了供应我们的化合物MN166（...
登录免费看全文
登录/注册
资讯热榜
更新时间